BioWorld MedTech

May 22, 2018

FDA gives nod to Cerenovus for Embotrap II

Cerenovus, a unit of New Brunswick, N.J.-based Johnson & Johnson Corp. (J&J), received 510(k) clearance for the Embotrap II to capture and remove blood clots from the brain following an ischemic stroke. Read More

Micro-cap Dx player Precipio launches pancreatic liquid biopsy from Dana-Farber

Debate over stent vs. balloon for restenosis revived yet again

GE Healthcare's partnership with Singapore's A*STAR sees progress in imaging modalities

New funding helps Australia's med-tech industry push upward

Other news to note

Appointments and advancements

Product briefs

BioWorld MedTech's Cardiology Extra

Today's news in brief

BioWorld

BioWorld briefs for April 9, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 8, 2025.

Many med-tech company supply chains protected from tariffs

BioWorld MedTech

In the wake of the pandemic, many leading med-tech companies took steps to on-shore and near-shore manufacturing, a move that could protect significant numbers of...

Caution tape displaying US flag, tariffs

Biopharma exempt from US reciprocal tariffs, but not untouched

BioWorld

At first glance, it appears that biopharmaceuticals dodged the latest U.S. tariff bullet; med-tech, not so much. According to the executive order President Donald...

Impact of Trump tariffs on med tech proving difficult to anticipate

BioWorld MedTech

The Trump administration’s declaration of a new round of tariffs did not sit well with trade associations, but the impact of those tariffs may vary somewhat by...